Key points are not available for this paper at this time.
The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of care. This suggests a growing belief in the oncology community that delaying progression in metastaticdiseaseisaworthygoal,evenifOSisnotimproved.Butisanew treatment that improves PFS really an advance for patients? Or is it only lowering the bar to declare active some of our much-heralded new molecular targeted therapies? We believe that as a community, this trend requires discussion and debate.
Booth et al. (Tue,) studied this question.